Article Information
History
- March 2, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Jamie Lopez Bernal1,2,3,*,
- Nick Andrews1,2,
- Charlotte Gower1,
- Julia Stowe1,
- Chris Robertson4,
- Elise Tessier1,
- Ruth Simmons1,
- Simon Cottrell5,
- Richard Roberts5,
- Mark O’Doherty6,
- Kevin Brown1,
- Claire Cameron7,
- Diane Stockton7,
- Jim McMenamin7 and
- Mary Ramsay1,2
- 1Public Health England, London, United Kingdom
- 2NIHR Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine, London, United Kingdom
- 3NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London, United Kingdom
- 4University of Strathclyde, Glasgow, United Kingdom.
- 5Public Health Wales, Cardiff, United Kingdom.
- 6Public Health Agency Northern Ireland, Belfast, United Kingdom.
- 7Public Health Scotland, Glasgow, United Kingdom.
- ↵*Corresponding author: jamie.lopezbernal2{at}phe.gov.uk
Posted March 02, 2021.
Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England
